NVAX Novavax, Inc.

NASDAQ
$10.65

Novavax, Inc. (NVAX) is confirmed to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.37 per share.

Novavax Beat Consensus Estimates, Raises Guidance
Thursday, November 5, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.37)
Rev est $50.61M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Novavax, Inc.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.